The Hellenic Pulmonary Society (EIA) is conducting a campaign for information and awareness of vaccination as to vaccination as a measure of respiratory prevention (RSV).

‘The campaign aims to inform but also to remind adults over 60 years of ageto groups but also to pregnant womenthat there is no cure for respiratory virus to treat respiratory virus only Prevention through vaccination“, Said the president of the Hellenic Pulmonary Society Professor of Pulmonology, Stelios Loukidis.

He added that “to date the data we have at our disposal state that the effect of respiratory virus as Endemic viral infection during November -February has a significant impact on the health system with several hospitalizations and unfortunately with high mortality“

The Secretary -General of the Hellenic Pulmonary Society Professor of Pulmonary Pulmonology, Petros Bakakos, said that “RSV presents to elderly adults and patients with chronic diseases, mainly respiratory and cardiovascular system, high rates of serious complications viral pneumonia. “

According to the instructions of the Hellenic Pulmonary Society, vaccination is recommended with any of the two vaccines available (RSVPref3, RSVPref), which have been approved by the European Medicines Agency and which are effective and safe:

– In all COPD patients, with particular emphasis on COPD patients and cardiovascular disease

– to all asthma patients

– In all patients with cystic fibrosis, severe interstitial pulmonary disease, severe pulmonary hypertension

– In all patients over 50 years of age with co -consciousness [σακχαρώδη διαβήτη, καρδιαγγειακά νοσήματα (καρδιακή ανεπάρκεια, στεφανιαία νόσο, σοβαρές βαλβιδοπάθειες, υπέρταση, αγγειακή νόσο του εγκεφάλου), χρόνια νεφρική νόσο, χρόνια ηπατοπάθεια, συγγενή ή επίκτητη ανοσοκαταστολή]

– to all adults over 60 years of age with or without co -hosts

The EIA also stresses the importance of vaccination with RSVPref, for women who are pregnant to protect their newborns during the first 6 months of life, where the risk of severe RSV infection is increased. Vaccination is recommended to take place at 32 to 36 weeks of pregnancy, ensuring the transfer of antibodies from mother to fetus via the placenta. In this way the infant is protected immediately after birth, when it is particularly vulnerable. International studies have shown that pregnant vaccination is safe and significantly reduces infants due to RSV infection.